A5049020371- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- HIV/AIDS drug development and treatment
- HIV, Drug Use, Sexual Risk
- Hepatitis Viruses Studies and Epidemiology
- HIV-related health complications and treatments
- Hemoglobinopathies and Related Disorders
- HIV Research and Treatment
- Iron Metabolism and Disorders
- COVID-19 and healthcare impacts
- Potassium and Related Disorders
- interferon and immune responses
- Telemedicine and Telehealth Implementation
- Hemophilia Treatment and Research
- Liver Diseases and Immunity
- Oral and gingival health research
- Biliary and Gastrointestinal Fistulas
- Esophageal and GI Pathology
- Medication Adherence and Compliance
- Systemic Lupus Erythematosus Research
- Atrial Fibrillation Management and Outcomes
- Chronic Kidney Disease and Diabetes
- Diabetes, Cardiovascular Risks, and Lipoproteins
Monash University
2009-2024
St Vincent's Hospital
2014-2024
The Alfred Hospital
2009-2023
Burnet Institute
2009-2023
The University of Melbourne
2008-2022
Alfred Health
2019-2021
St. Vincent's Hospital
2008-2017
Saint Vincent's Catholic Medical Center
2008-2017
St. Vincent's Birmingham
2008-2017
Pomona College
2014
Although threshold levels for hepatitis B surface antigen (HBsAg) and e (HBeAg) titers have recently been proposed to guide therapy chronic (CHB), their relationship circulating virus (HBV) DNA intrahepatic HBV replicative intermediates, the significance of emerging viral variants, remains unclear. We therefore tested hypothesis that HBsAg HBeAg may vary independently replication in vivo . In all, 149 treatment-naïve CHB patients were recruited (HBeAg-positive, n = 71; HBeAg-negative, 78)....
Abstract Background/Aims Endoscopic screening for high‐risk gastro‐oesophageal varices ( GOV ) is recommended compensated cirrhotic patients with transient elastography identifying increasing numbers of cirrhosis without portal hypertension. Using liver stiffness measurement LSM ± platelet count, the aim was to develop a simple clinical rule exclude presence in Child–Pugh A cirrhosis. Methods retrospective analysis 71 diagnosed by >13.6 kP a) who underwent gastroscopy conducted....
To achieve the World Health Organization hepatitis C virus (HCV) elimination targets, it is essential to increase access direct-acting antivirals (DAAs), especially among people who inject drugs (PWID). We aimed determine effectiveness of providing DAAs in primary care, compared with hospital-based specialist care.We randomized PWID HCV attending care sites Australia or New Zealand receive at their site local hospital (standard [SOC]). The outcome was whether treated had a noninferior rate...
The prevalence of hepatitis B virus (HBV) infection in Australia is nearly 1%. In certain well defined groups the far greater, yet an estimated 27% people living with HBV remain undiagnosed. Appropriate screening improves detection, increases opportunity for treatment, and ultimately reduces significant morbidity mortality associated development liver fibrosis hepatocellular carcinoma (HCC).This statement highlights important aspects management Australia. There have been recent changes...
Reducing the burden of hepatitis C virus (HCV) related liver disease will require treating people who inject drugs (PWID), group at most risk infection and transmission. We determine cost-effectiveness PWID with interferon-free direct-acting antiviral therapy in Australia.Using a deterministic model HCV treatment progression, including fixed rate re-infection, expected healthcare costs quality-adjusted life years (QALYs) cohort newly HCV-infected were calculated for: no treatment; after...
Abstract Background Gay and bisexual men (GBM) are a key population affected by human immunodeficiency virus (HIV) hepatitis C (HCV) coinfection. We aimed to measure HCV treatment effectiveness determine the impact of scale-up on prevalence incidence longitudinally among GBM. Methods The co-EC Study (Enhancing Care Treatment Among HCV/HIV Coinfected Individuals Eliminate Hepatitis Transmission) was an implementation trial providing direct-acting antiviral in Melbourne, Australia, during...
Liver disease frequently complicates cystic fibrosis (CF), with CF liver (CFLD) a leading cause of death. biopsy is rarely performed because the patchy nature disease. Transient elastography can reliably stage via stiffness measurement (LSM).To evaluate LSM as diagnostic tool in adults CFLD.Fifty adult patients were prospectively studied: 25 CFLD and without CFLD. The presence portal hypertension (PHT) was assessed according to strict established criteria based on serial biochemistry...
IL28B genotype predicts response to pegylated interferon (peg-IFN)-based therapy in chronic hepatitis C. However, the utility of genotyping B (CHB) cohorts treated with peg-IFN is unclear. It was investigated whether associated treatment outcomes a predominantly Asian CHB cohort.This retrospective analysis patients 48 weeks monotherapy. (rs12979860) determined (TaqMan allelic discrimination kit). Baseline virus (HBV)-DNA, alanine aminotransferase, and liver histology were available. The...
to determine if intrahepatic immune activation is increased in HIV-hepatitis B virus (HBV) co-infected patients compared HBV mono-infected and whether this reduced following HBV-active antiretroviral therapy (ART) HIV-HBV patients.: Case-control observational study.we examined liver biopsies for markers of T-cell monocyte infiltration activation, natural killer cells, hepatic stellate cell (HSC) (staining alpha smooth muscle actin) apoptosis [using terminal dUTP nick-end labelling (TUNEL)]...
Liver-related mortality is increased in the setting of HIV-hepatitis B virus (HBV) coinfection. However, interactions between HIV and HBV to explain this observation have not been described. We hypothesized that infection hepatocytes directly affects life cycle HBV. infected human hepatic cell lines expressing (Hep3B AD38 cells) or (Huh7, HepG2, AD43 with laboratory strains (NL4-3 AD8), as well a vesicular stomatitis (VSV)-pseudotyped enhanced green fluorescent protein (EGFP). Following...
Hepatitis B virus (HBV)-specific T cells play a key role both in the control of HBV replication and pathogenesis liver disease. Human immunodeficiency type 1 (HIV-1) coinfection presence or absence e (precore) antigen (HBeAg) significantly alter natural history chronic infection. We examined HBV-specific T-cell responses treatment-naïve HBeAg-positive HBeAg-negative HIV-1-HBV-coinfected (n = 24) HBV-monoinfected 39) Asian patients. Peripheral blood was stimulated with an overlapping peptide...
We investigated the relationship between microbial translocation, immune activation, and liver disease in human immunodeficiency virus (HIV)/hepatitis B (HBV) coinfection. Lipopolysaccharide (LPS), soluble CD14, CXCL10, CCL-2 levels were elevated patients with HIV/HBV Levels of LPS, declined following receipt HBV-active combination antiretroviral therapy (cART), but CXCL10 level remained elevated. No markers associated severity on biopsy (n = 96), interleukin 6 (IL-6), 10 (IL-10), tumor...
To evaluate the long-term treatment outcomes of tenofovir therapy in patients a real world Australian tertiary care setting.We performed retrospective analysis among treatment-naïve and treatment-experienced receiving minimum 3 mo through St Vincent's Hospital Melbourne, Australia. We included [tenofovir disoproxil fumarate (TDF)] monotherapy, as well treated with TDF combination second antiviral agent. Patients were excluded if they demonstrated human immune-deficiency virus/hepatitis C...
Background: Hepatitis C virus (HCV) reinfection after successful treatment may reduce the benefits of cure among people who inject drugs. Objective: To evaluate rate HCV for 3 years receiving opioid agonist therapy (OAT). Design: A 3-year, long-term, extension study persons enrolled in CO-STAR (Hepatitis Patients on Opioid Substitution Therapy Antiviral Response) (ClinicalTrials.gov: NCT02105688). Setting: 55 clinical trial sites 13 countries. Patients: Aged 18 and older with chronic...
Abstract Background: Lamivudine resistance is associated with long‐term monotherapy for chronic hepatitis B and can lead to potentially serious clinical consequences. Scant information exists regarding the influence of virus variants in development resistance. The present study was designed identify factors predictive lamivudine resistance, a particular focus on role precore basal core promoter setting e antigen‐negative disease. Methods: Eighty‐five patients, representing four major...
Abstract Background. Advanced fibrosis occurs more commonly in human immunodeficiency virus (HIV)-hepatitis B (HBV) coinfected individuals; therefore, monitoring is important this population. However, transient elastography (TE) data HIV-HBV coinfection are lacking. We aimed to assess liver using TE a cross-sectional study of individuals receiving combination HBV-active (lamivudine and/or tenofovir/tenofovir-emtricitabine) antiretroviral therapy, identify factors associated with advanced...
Abstract Virological failure occurs in a small proportion of people treated for hepatitis C virus (HCV) with direct‐acting antiviral (DAA) therapies. This study assessed retreatment virological large real‐world cohort. REACH‐C is an Australian observational ( n = 10,843) evaluating treatment outcomes sequential DAA initiations across 33 health services between March 2016 to June 2019. data were collected until October 2020. Of 408 (81% male; median age 53; 38% cirrhosis; 56% genotype 3), 213...
Background/Aims Long-term follow-up studies validating the clinical benefit of sustained virological response (SVR) in people with chronic hepatitis C (CHC) infection are lacking. Our aim was to identify rates and predictors liver fibrosis progression a large, well characterized cohort CHC patients whom paired assessments were performed more than 10 years apart. Methods who had undergone baseline biopsy pre-2004 follow up assessment later (biopsy or stiffness measurement (LSM) using...